<DOC>
	<DOCNO>NCT02275936</DOCNO>
	<brief_summary>This Phase 1b study F508del-CFTR homozygous CF patient conduct assess safety N91115 sole cystic fibrosis transmembrane conductance regulator ( CFTR ) modulator dos near expect therapeutic exposure level preparation Phase 2 study N91115 add CFTR modulator combination lumacaftor/ivacaftor launch .</brief_summary>
	<brief_title>Study N91115 Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description>Study procedure , frequency timing provide attach study schema . Adverse event concomitant medication monitor throughout study inform consent sign end study participation . A Data Monitoring Committee ( DMC ) also review unblinded safety data monthly basis throughout study . Limitations bronchodilator pulmonary assessment prior study drug dose describe except emergent situation . - Short act β-agonists anticholinergic hold least 4 hour - Long act β-agonists dosed twice daily hold least 12 hour - Long act β-agonists dose daily long act anticholinergic hold least 24 hour Screening ( Day -28 Day -3 ) : Patients sign inform consent undergo procedure determine eligibility include pregnancy testing , demographic information , medical history , genotype historical confirmation blood sample confirmation ( applicable ) , height weight , 12-Lead electrocardiogram ( ECG ) , 48-hour Holter monitoring , chemistry , hematology , full physical examination , sweat chloride , smoke alcohol history , spirometry , sputum microbiology , urinalysis vital sign . Day 1 Predose ( Day -2 -1 ) Patients return clinic reconfirm eligibility ass change medical history pregnancy status . An abbreviated physical examination focus cardiovascular , pulmonary gastrointestinal system plus assessment weight conduct . The following obtain : 12-lead ECG , abbreviate physical exam , blood DNA ( optional ) , blood leukocyte messenger ribonucleic acid ( mRNA ) , blood inflammatory biomarkers , cystic fibrosis questionnaire-revised ( CFQ-R ) , O2 Sat , patient global impression change ( PGIC ) , safety lab , serum pharmacokinetics ( PK ) , spirometry , sputum microbiology , sweat chloride ( SC ) ( 2 week since screen value obtain ) , vital sign . Sites may choose perform assessment Day -2 , Day -1 Day 1 predose except serum PK start Day 1 predose vital sign do Day 1 predose . Dosing Food Intake : Patients take dose study drug every 12 hour approximately time morning night . There restriction relate food intake . Dosing Days 1 2 : On Day 1 , patient observe least 4 hour follow first dose study drug . Patients return clinical site Day 2 predose PK sample 24 hour first dose . Patients observe least 2 hour second dose Day 2 . Days 3-28 : Patients self-administer study drug approximately time morning even exception morning dose clinic Days 7 , 14 , 21 28 , administer witness clinic . Day 7 ( Dosing Clinic ) : On Day 7 , patient return clinic monitor change health status abbreviate physical exam , 12-Lead ECG , O2 Sat , safety lab , PK , spirometry , study drug compliance , SC vital sign . Day 14 ( Dosing Clinic ) : On Day 14 , patient return clinic monitor change health status abbreviate physical exam , urine pregnancy , 12-lead ECG , blood inflammatory biomarkers , CFQ-R , O2 Sat , safety lab , PK , spirometry , study drug compliance , SC vital sign . Day 21 ( Dosing Clinic ) : On Day 21 , patient return clinic monitor change health status abbreviate physical exam , 12-Lead ECG , O2 Sat , safety lab , PK , spirometry , study drug compliance , SC vital sign . Day 28 ( Dosing Clinic ) : On Day 28 patient return clinic monitor change health status abbreviate physical exam , 12-Lead ECG , blood DNA ( optional ) , blood leukocyte mRNA , blood inflammatory biomarkers , CFQ-R , urine pregnancy , O2 Sat , PGIC , safety lab , PK , spirometry , sputum microbiology , study drug compliance , SC , weight , vital sign . Day 42 ( Final study day 2 week last dose ) : On Day 42 ( ± 2 day ) study follow-up assessment include : abbreviated physical exam , blood inflammatory biomarkers , O2 Sat , PGIC , spirometry , SC , weight , vital sign .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Male female , age ≥ 18 year confirm diagnosis CF , homozygous F508delCFTR mutation base historical result generate Ambry Genetics within past two year unavailable , confirm test do within past 28 day 2 . Sweat chloride ≥ 60 ( milliequivalent ) mEq/L , quantitative pilocarpine iontophoresis test ( QPIT ) screen 3 . Weight ≥ 40 kg screen 4 . Forced expiratory volume ( FEV1 ) ≥ 40 % predict normal age , gender , height ( Hankinson standard ) pre postbronchodilator value , screen 5 . Oxygen saturation pulse oximetry ≥ 90 % breathe ambient air , screen 6 . Hematology , clinical chemistry urinalysis result clinically significant abnormality would interfere study assessment screen 1 . Any acute infection , include acute upper low respiratory infection pulmonary exacerbation require treatment hospitalization within 2 week Study Day 1 2 . Any change chronic therapy CF lung disease ( e.g. , Ibuprofen , Pulmozyme® , hypertonic saline , Azithromycin , Tobi® , Cayston® ) within 4 week Study Day 1 3 . Blood hemoglobin &lt; 10 g/dL screen 4 . Serum albumin &lt; 2.5 g/dL screen 5 . Abnormal liver function define ≥ 3 x upper limit normal ( ULN ) 3 follow : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gglutamyl transferase ( GGT ) , alkaline phosphatase ( ALP ) , total bilirubin screen 6 . History abnormal renal function ( creatinine clearance &lt; 50 mL/min use CockcroftGault equation ) within year screen 7 . History , include screen assessment , ventricular tachycardia ventricular arrhythmias 8 . History , include screen assessment , prolong cardiac QT interval and/or QTcF ( QT Fridericia 's correction ) interval ( &gt; 450 msec ) 9 . History solid organ hematological transplantation 10 . History alcohol abuse drug abuse ( include cannabis , cocaine , opioids ) year prior screen 11 . Use continuous ( 24 hr/day ) nocturnal supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>N91115</keyword>
	<keyword>Cavosonstat</keyword>
</DOC>